Member Info for HeimlichIII

Teabiscuit. I appreciate what you’re saying, but what makes you believe that these new products from competitors won’t have to go through exactly the same process...possibly even longer with further increase in applications as time progresses?

Completely agree longrun. People on here act like their sat there twiddling thumbs waiting for the phone to ring from the FDA. They will be flat out working on sales and production. Don’t forget, this is a massive opportunity for the company and the employees there as well, they will be busting a gut to make it count regardless of whether the tell you what their doing every week or not.

Faith in the product and the demand, that’s the key.

Looks like that article is from 10th April? Where are they now??

Correct me if I’m wrong:

GDR - Gold Standard test, practically no sales (mcap £42m)
NCYT - Golf Standard test, sales (mcap £195m)
ODX - Questionable test, debate over value of antibody tests, issue of false positives, some sales (mcap £104m)
AVCT - No test, no sales (mcap £324m)
SNG - Treatment to massively reduced critical patients, so should support testing, no sales (mcap £297m)

For profit making potential, where would you put your money?

...think it’s last night’s jalfrezi

Completely agree. This is a random investor trying his luck for an update.

Check the RNS, this is covered I think. Although predictably they just say it’s out of their hands. She does at least recognise the frustration of the shareholder.

Are you sure it’s not just the Q&A included on the RNS of 17th July? They said it would be ‘by close of play on 20th’, why would they include Q&A on 17th if there was another coming?

Surely today’s SNG developments emphasise the need to mass testing. Test, Track and Treat ahead of vaccine next year.

...the AVCT mcap is 10 x ours?? Don’t get it. Don’t get it at all.

2m a month is nowhere near enough. That’s circa 350,000 tests at a production rate of 10,000 per hour....about 4 days work.

I was under the impression from DB’s presentation that the hearing test alone warranted an mcap in excess of where it is now. Was I wrong? Thought he said £45-£60m sales on that alone. Could somebody correct / update me?

Absolutely, they talk about 2 million tests by next month...the chat at one stage was for a million tests a day in India. Even if you cut that in half they’ll have 4 days worth of test per 3 weeks work. Supply vs demand.

“The company paid the evaluation fee in full”

Trilla - pretty sure it says the £50k was paid

Yeah. Come on people, are you suggesting the payment isn’t important. Of course it is. Further clarification this is happening, it’s assumed, sure, but now it’s confirmed and paid. Excellent.

Actually I think the issue is that most people don’t read past the title of the RNS

I struggle to work out if it’s derampers or just because people are lacking intelligence.

Daily infections circa 4k at the moment

Exactly. Looks very much to me like AVCT are trying to cash in on their increased expose to build longer term investors.